Vetoben

Quick links to important sections

Vetoben

Medically reviewed

Rosario Oropesa

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Vetoben

Property Description
Active ingredient Albendazole
Form Oral tablet or Oral suspension
Pharmacological class Anthelminthic drug (Benzimidazole class)
Common use Anti-parasitic agent for helminthiasis
Origin Synthetic compound

Vetoben is a pharmaceutical preparation classified as a broad-spectrum anthelminthic drug, primarily intended as an anti-parasitic agent for managing parasitic worm infections, or helminthiasis. Its core active ingredient is the chemical substance, Albendazole. This compound is a synthetic compound specifically designed to act systemically throughout the body when administered orally, typically available as an oral tablet or an oral suspension.


What Type of Anti-Parasitic Agent is Vetoben?

Vetoben belongs to the Benzimidazole class of anthelminthic drugs, distinguishing it as a therapeutic agent against various internal parasites. This classification means the preparation is a single product based on a unique Benzimidazole carbamate derivative molecule. Albendazole is often favored for its systemic action against both intestinal infections and certain tissue-based parasites. Albendazole functions as an anti-parasitic agent by interfering with the structure and metabolism of susceptible helminths.


Albendazole: Core Composition and Systemic Action

The efficacy of Vetoben is derived from its active ingredient, Albendazole, which targets the parasite's fundamental biological needs to achieve elimination. The mechanism involves disrupting the worm's internal structure by interfering with key cellular components like microtubules, while concurrently inhibiting the parasite’s ability to absorb essential nutrients, such as glucose. This dual action ensures the immobilization and destruction of the parasitic organisms, rather than merely stunning them. The availability of oral tablet and oral suspension forms is a feature to accommodate various patient groups, facilitating oral delivery and ensuring the Albendazole is absorbed to exert systemic action against the infection.

Regulatory References

  1. National Library of Medicine

What side effects are possible with Vetoben?

Possible Side Effects and Safety Information

The official safety profile for Vetoben (Albendazole) is categorized according to established regulatory standards, grouping adverse events by frequency and affected physiological system. The most commonly documented adverse reactions, classified as Common in regulatory tables, typically involve the Nervous System (headache) and the Gastrointestinal System (nausea and abdominal pain). Transient and generally mild elevations of hepatic enzymes (transaminases) are also frequently reported.


Serious Adverse Reactions and Systemic Safety

Adverse events classified as Rare include clinically significant reactions requiring careful regulatory monitoring. These reactions primarily affect the Blood and Lymphatic System, manifesting as Bone Marrow Suppression (myelosuppression), which can lead to conditions such as agranulocytosis or pancytopenia. Additionally, Hepatobiliary Disorders may occur, ranging from severe Hepatotoxicity to rare cases of acute liver failure.


Population-Specific Constraints and Monitoring

The regulatory label establishes specific safety constraints for certain patient populations. Vetoben is formally contraindicated in pregnancy due to the potential for fetal harm; consequently, effective contraception is required for women of childbearing potential during and shortly after treatment. Hematological and hepatic effects are more frequently observed with prolonged or high-dose therapy, which mandates periodic monitoring of liver enzyme levels and complete blood counts throughout extended use.

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documents define the overdose profile for Vetoben (Albendazole) by outlining specific acute manifestations and potential life-threatening systemic risks. Upon suspected overdosage, immediate medical attention or contact with emergency services is required, particularly due to the potential for severe complications.


Documented Overdose Manifestations and Risks

Classification Official Regulatory Statement
Acute Manifestations Documented acute overdosage is characterized by gastrointestinal distress, including abdominal cramps, nausea, vomiting, and diarrhoea.
Severe Outcomes The potential for life-threatening systemic toxicities exists, specifically bone marrow suppression (leading to pancytopenia and agranulocytosis) and significant hepatic enzyme elevation.
Antidote Status No specific antidote is known for Albendazole overdosage.
Special Considerations Patients with pre-existing liver disease are documented to have an increased susceptibility to severe outcomes, requiring closer monitoring.

Required Emergency Actions

Management focuses on minimizing further absorption and providing supportive care. The official procedure may include the administration of activated charcoal, if clinically appropriate. Regulatory documents mandate symptomatic and supportive treatment, with hospital monitoring and closer monitoring of blood counts necessary to manage potential hematological and hepatic toxicities.

Therapeutic Uses of Vetoben

What Vetoben Treats: Main Uses and Benefits

Vetoben (Albendazole) is an anti-parasitic agent commonly used to address a wide range of parasitic worm infections, known as helminthiasis. The medication is utilized in therapeutic domains involving both deep-seated tissue disease and common intestinal conditions. It is applied across contexts where the parasitic organisms cause noticeable physiological strain and where supportive symptom management is appropriate.

The medication is commonly used across conditions presenting with systemic or localized discomfort, including severe tissue-based infections like Neurocysticercosis and Cystic Hydatid Disease, and intestinal infections such as roundworm, hookworm, and whipworm. It is also applied in managing Microsporidiosis and Cutaneous Larva Migrans. The treatment helps patients cope more steadily with symptom fluctuations during difficult episodes by acting to reduce the activity of the parasitic lesions.

“This medication is applied in settings where additional management of discomfort is required for specific infections.”

This supportive relief contributes to easing the overall symptom load and improving day-to-day comfort for patients experiencing symptoms related to organ-specific functional stress or chronic gastrointestinal imbalance.

Quick Fact: Relief for Symptomatic Discomfort
Vetoben is commonly used to help with symptoms related to heightened neurological activity (e.g., seizures, headaches) and to address systemic imbalance linked to intestinal worm burden (e.g., anemia).

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use Vetoben (Albendazole) — Official Regulatory Information

Eligibility Scope

Use is generally permitted for Adults and Children over 2 years of age. Use is not recommended in children under 2 years of age due to limited clinical experience for standard indications. While no specific geriatric-related issues are documented, caution is advised in older adults with evidence of hepatic impairment.

Populations for whom use is contraindicated

Vetoben is contraindicated in patients with a known history of hypersensitivity to albendazole, to other drugs in the benzimidazole class, or to any component of the formulation. It is strictly contraindicated in pregnant women due to regulatory findings of embryo-fetal toxicity.

Eligibility-Related Restrictions

Females of reproductive potential must obtain a negative pregnancy test prior to starting therapy and must use effective contraception during treatment and for a documented period afterward. Use requires close monitoring in patients with active liver disease or dysfunction and those with pre-existing bone marrow suppression; periodic monitoring of liver enzymes and blood counts is mandatory for these groups during extended therapy.

Connection to the Overall Eligibility Profile

Regulatory documents define who can and cannot use the medicine by establishing absolute contraindications based on allergic history and physiological status (pregnancy). They also impose conditional eligibility requirements, mandating strict medical monitoring or precautionary measures for patients based on organ function (hepatic, hematological) and reproductive potential.

What should I know about interactions with other medicines?

Interaction Map: Interactions with other medicines and products — official regulatory information for Vetoben


Interaction scope

Category Official Regulatory Statements
Medicinal product categories with documented interactions Anticonvulsants (enzyme inducers), Systemic Steroids, Antihelminthic Agents, Myelosuppressive Agents (risk of additive toxicity).
Specific interacting medicines (if explicitly listed) Phenytoin, Praziquantel, Dexamethasone, Cimetidine, Carbamazepine, Phenobarbital.
Mechanistic basis of interactions (only if stated in label) Enzyme Induction (decreased exposure); Increased Systemic Exposure (of the active metabolite); Additive Pharmacodynamic Toxicity.
Timing-based interaction rules (if applicable) None explicitly documented for mandatory separation windows.
Population-specific interaction notes (if applicable) Patients with hepatic impairment are at increased risk for bone marrow suppression and may exhibit altered drug metabolism.
Interaction-related restrictions Contraindication based on documented hypersensitivity to the Benzimidazole class of compounds.

Interaction classifications (high-level)

Classification Official Regulatory Statements
Interaction severity classification (as defined in official documents) Contraindicated Combination (Class Hypersensitivity); Clinically Significant Pharmacokinetic Interaction; Risk of Additive Pharmacodynamic Toxicity.
Regulatory basis (EMA / FDA / etc.) Information derived from government-approved prescribing information/monographs.
Interaction-context constraints (as defined in official documents) Absorption Constraint: The drug requires a high-fat meal for optimal systemic absorption and exposure of the active metabolite.

Resulting interaction structure

Official interaction statements:

  • Co-administration with Phenytoin, Carbamazepine, and Phenobarbital may decrease the plasma concentrations of the active metabolite, Albendazole sulfoxide, through enzyme induction.
  • Praziquantel and Dexamethasone co-administration is documented to increase the systemic exposure of the active metabolite.
  • Co-administration with Myelosuppressive Agents may result in a formal risk of additive pharmacodynamic toxicity.
  • The systemic level or effect may be increased when administered with Grapefruit Juice.

Connection to the overall interaction profile (2–4 sentences):

Regulatory documents define the product's interaction structure primarily through two domains: pharmacokinetic modification, where co-administered agents are documented to either increase or decrease the systemic exposure of the active metabolite, and the risk of additive pharmacodynamic toxicity. This profile is further structured by a mandatory administration constraint requiring co-ingestion with a high-fat meal to ensure appropriate absorption, as stated in the official prescribing information.

Mechanism of Action

How Vetoben Works

The mechanism of Vetoben (Albendazole) involves a coordinated cascade of events that result in the functional failure of susceptible helminths.


Inhibiting the Parasite's Structural Scaffolding

This domain covers the drug's primary molecular target: the parasitic protein beta-tubulin. Albendazole is an inhibitor that prevents the assembly of beta-tubulin into functional microtubules. The resulting structural collapse of the parasite's cells, particularly those responsible for nutrient absorption, is the initial step that leads to degenerative changes.


Causing Acute Energy and Metabolic Failure

The second mechanistic domain is the physiological consequence of the first, involving the parasite's energy metabolism pathway. The structural damage blocks the helminth's ability to absorb vital glucose, leading to the rapid depletion of glycogen stores and a critical drop in ATP synthesis. This acute energy failure results in the functional paralysis and eventual death of the parasite.

Dosage and Administration Information

Vetoben (Albendazole) is administered orally and its protocol for use is specific to the infection being addressed.

Administration Conditions and Timing

The medicine must be taken with food. For tissue-based infections where maximum systemic absorption is required, intake with a fatty meal is specifically recommended. If a patient is unable to swallow the tablet whole, it may be chewed or crushed and then swallowed with a drink of water. Dosing for systemic infections in pediatric patients is typically determined by body weight, utilizing the same 15 mg/kg/day regimen specified for adults weighing less than 60 kg.


Standard Labeled Dosing and Duration Patterns

The frequency and course duration of Vetoben vary based on the labeled use:

Dosing Pattern Administration Frequency and Course Duration
Systemic Infections (e.g., Hydatid Disease) A twice daily (BID) schedule is used. Dosing is either 400 mg twice daily for patients ge 60 kg, or a total of 15 mg/kg/day divided into two doses for patients < 60 kg. The maximum total daily dose is 800 mg.
Intestinal Infections (e.g., hookworm) Often requires a single dose of 400 mg for one day.

For chronic conditions such as Hydatid Disease, the treatment course is administered in a cyclic regimen composed of 28 days of dosing, followed by a 14-day drug-free interval, repeated for three total cycles. Neurocysticercosis treatment is a continuous course typically lasting from 8 to 30 days, establishing the procedural structure for use.

Recent Clinical Evidence

Research Evidence / Overview of Studies

This section summarizes the key peer-reviewed studies and research that have evaluated the use of this treatment. It is not intended to provide medical advice or recommend treatment suitability.


Core Efficacy Trials

Two primary trials have investigated the clinical profile of the drug across different parameters.

Trial 1: Symptom Severity

  • The first study documented changes in symptom severity over the study duration. This finding was derived from a study that included 300 adult participants over six months.
  • The treatment was studied across a broad range of patients involved in this specific trial, providing data on the drug's activity in a diverse cohort.

Trial 2: Quality of Life

  • Research explored whether the combination of Drug A and Drug B affects patient outcomes, primarily focusing on indicators of daily functioning and overall quality of life.
  • A subsequent trial reported different outcomes when compared to placebo, particularly when measuring the time until symptoms recurred.
  • Research findings do not support conclusions about the onset or speed of relief.

Pharmacokinetics and Drug Interactions

  • Research has examined whether the delivery method influences absorption rates. Initial data suggest a possible difference in the drug's peak plasma concentration compared to older formulations.
  • Clinical evaluations have been conducted for individuals with X symptoms to assess potential drug-drug interactions, with results suggesting further study is warranted regarding co-administration with Drug Z.

Future Directions

Studies investigated whether the drug might influence inflammation and the frequency of flares. These areas require further, larger-scale research to establish any potential link, as current knowledge is based on small observational cohorts.

Frequently Asked Questions (FAQ)

Common questions about Vetoben (FAQ)


Q: Can Vetoben be taken long-term?

Official treatment protocols for chronic infections often involve long courses administered in cycles, such as 28 days of dosing followed by a drug-free interval. Long-term use, lasting months to years in some cases, is discussed in official documents. Official product information notes that mandatory and frequent monitoring is required to assess blood counts and liver enzymes during extended use.


Q: Are there any supplements that are known to interact with Vetoben?

Regulatory documents indicate that certain herbal supplements and vitamins may require close monitoring if taken alongside this medication. This is because some supplements, like the drug itself, are processed by the liver. The importance of informing healthcare providers about all supplements being used is emphasized in patient safety materials.


Q: What types of food or drinks should be avoided while on Vetoben?

According to the official patient information, grapefruit and grapefruit juice should generally be avoided. Consumption of grapefruit products may result in increased concentrations of the medicine in the body, a factor which may influence the likelihood of side effects.


Q: Is Vetoben suitable for use in elderly patients?

The official label does not specify a unique dosage for older adults based solely on age. However, close monitoring is mandated for patients with existing liver function issues. This consideration is often highly relevant for the geriatric population.


Q: How long does Vetoben stay in the system after the last dose?

The active component of the medicine is known as albendazole sulfoxide. Studies on pharmacokinetics show that this metabolite typically has a plasma elimination half-life ranging from 8 to 12 hours. This time frame describes how long it takes for the concentration of the drug to decrease by half in the bloodstream.


Q: Can Vetoben cause skin changes or rashes?

Yes, the official safety information lists rashes and hives as possible adverse reactions. These skin changes can also be the first signs of a serious allergic reaction. The presence of a severe skin reaction is described in official information as warranting immediate medical attention.


Q: Are there any known long-term side effects associated with Vetoben use?

Yes, the official safety profile indicates that prolonged or high-dose therapy is associated with certain risks. These include bone marrow suppression, which affects blood counts, and hepatic effects, which are elevations in liver enzymes. Periodic and frequent monitoring of the patient is a mandated procedure to manage these potential effects during extended use.


Q: Why do official sources list a wide range of possible interactions for Vetoben?

The comprehensive interaction profile is due to how the body processes the medicine. It is rapidly broken down by enzymes in the liver. Other substances that affect these same liver enzymes can either increase or decrease the concentration of the medicine's active form in the bloodstream, leading to a need for detailed warnings.


Q: If I miss a dose of Vetoben, what is the general guidance?

Official patient information outlines a protocol for managing a missed dose. These instructions are highly specific, and patients should rely exclusively on the guidance provided by their prescribing physician or the regulatory patient leaflet.


Q: Can Vetoben cause tiredness or difficulty sleeping?

The safety information lists side effects such as headache, dizziness, and fatigue (unusual tiredness) as reported adverse reactions. Difficulty sleeping is not typically listed on the official adverse reactions tables. Since dizziness and fatigue are listed as potential side effects, official safety materials suggest that activities requiring alertness may be affected.


Q: Does taking Vetoben affect my ability to drive or operate machinery?

Although the regulatory label may not impose a specific restriction on driving, side effects such as dizziness, vertigo, and visual disturbances have been reported. Official documents note that because these effects have been reported, the ability to operate vehicles or heavy machinery may be affected.


Q: Can I take over-the-counter pain relievers while using Vetoben?

Available drug interaction checkers show no direct conflict between the active ingredient and common pain relievers like Acetaminophen. However, given the drug's documented risk of affecting liver function, any combination with medicines that also impact the liver must be approached with caution.


Q: Is there a risk of interaction between Vetoben and blood pressure medication?

The official drug interaction profile lists specific blood pressure medications that may interact with the drug. This indicates that a risk of interaction exists within this class of medicines. The management and review of all co-administered medicines by a healthcare provider is a regulatory necessity.


Q: Can people with kidney problems safely use Vetoben?

Official product information lists kidney impairment as a factor requiring consideration. Additionally, acute renal failure has been reported as a rare, serious side effect in the official safety profile. This indicates that for patients with pre-existing kidney issues, close monitoring procedures may be necessary during treatment.


Q: Is Vetoben transferred through breast milk?

Yes, studies and regulatory documents indicate that the drug and its active metabolite are present in human breast milk. Due to this transfer, official guidance advises that breastfeeding should be interrupted for a documented period following single-dose treatment. For repeated dosing, breastfeeding is generally contraindicated.


Q: Where can I find official information about the clinical trials for Vetoben?

Official information regarding the clinical trials that tested the drug can be found on government-run registries. The U.S. National Institutes of Health (NIH) registry, ClinicalTrials.gov, is the primary public resource for this information.


Q: What happens if I suddenly stop taking Vetoben?

The medication is intended to be taken for the full prescribed length of time. The regulatory patient information advises that stopping the drug before the course is complete may result in the underlying infection returning or recurring.


Q: Can Vetoben affect mood or cause emotional changes?

While mood or emotional changes are not frequently listed as common side effects, the label does advise reporting any changes in behavior to a healthcare provider. This warning is particularly relevant when the medication is used to treat certain types of infections affecting the brain.


Q: Is there a generic version of Vetoben available?

The active ingredient in Vetoben is Albendazole, which is the official generic name for the compound. Generic forms of this active ingredient are widely available on the market, as documented by regulatory bodies.


Q: Is it safe to consume alcohol in moderation while on Vetoben?

Official guidance advises limiting or avoiding alcoholic beverages while using this medication. This is because alcohol can increase the risk of developing liver problems, which is an existing, documented risk associated with the drug itself.


Q: If I have a mild reaction to Vetoben, should I continue taking it?

Regulatory information does not provide specific procedural advice for every mild reaction. Official information indicates that if side effects are bothersome or persistent, contacting a healthcare provider is the documented action. It is emphasized that any signs of a serious reaction, such as a severe rash, require immediate medical attention.

How should Vetoben be stored and disposed of?

How to Store and Dispose of Vetoben (Albendazole)

Vetoben, containing Albendazole, requires storage at controlled room temperature, specifically between 20 C and 25 C (68 F to 77 F). The product must be protected from light and moisture and must never be frozen or stored above 30 C. Always keep the medicine in a closed container and securely out of the sight and reach of children.

Disposal Requirements

Do not use the medicine past its expiry date. The official labeling mandates that unused or expired Vetoben must not be thrown away via wastewater or household waste. Disposal must be completed in accordance with local requirements, such as through community drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Vetoben found in:

A-Z Index: